Michael Krainock
Overview
Explore the profile of Michael Krainock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ohara S, Suda K, Sudhaman S, Hamada A, Chiba M, Shimoji M, et al.
JTO Clin Res Rep
. 2025 Feb;
6(3):100762.
PMID: 39990137
Introduction: Molecular residual disease detected by circulating tumor DNA (ctDNA) has been reported to be predictive of patients' outcomes in various types of cancers after curative intent treatment. Nevertheless, additional...
2.
Radigan R, Kao C, Krainock M, Liu M, Gupta V, Alexander L, et al.
Sci Rep
. 2025 Feb;
15(1):6126.
PMID: 39971963
Distant metastases account for ~ 90% of cancer deaths and major responses with systemic therapy alone for metastatic cancers are so rare that the National Cancer Institute launched the Exceptional...
3.
Oh Y, Yoon S, Lee J, Park J, Lee S, Hong T, et al.
Thorac Cancer
. 2024 Apr;
15(13):1095-1102.
PMID: 38558374
Background: Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for detection of minimal residual disease (MRD), monitoring treatment response, and early detection of recurrence in cancer...
4.
Martin T, Dinerman A, Sudhaman S, Budde G, Palsuledesai C, Krainock M, et al.
J Thorac Cardiovasc Surg
. 2024 Jan;
168(5):1349-1359.e2.
PMID: 38244856
Objective: The study objective was to evaluate the impact of monitoring circulating tumor DNA on the detection and management of recurrence in patients with resected early-stage non-small cell lung cancer....
5.
Lebow E, Shaverdian N, Eichholz J, Kratochvil L, McCune M, Murciano-Goroff Y, et al.
Front Oncol
. 2023 Oct;
13:1253629.
PMID: 37795442
Background: Sensitive and reliable biomarkers for early detection of recurrence are needed to improve post-definitive radiation risk stratification, disease management, and outcomes for patients with unresectable early-stage or locally advanced...
6.
Pellini B, Madison R, Childress M, Miller S, Gjoerup O, Cheng J, et al.
Clin Cancer Res
. 2023 Sep;
29(22):4596-4605.
PMID: 37702716
Purpose: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced driver-negative non-small cell lung cancer (NSCLC), with maintenance therapy given after induction. However, there is significant clinical variability in the...
7.
Kasi P, Chakrabarti S, Sawyer S, Krainock M, Poklepovic A, Ansstas G, et al.
BMJ Open
. 2022 May;
12(5):e060342.
PMID: 35636789
Introduction: Immunotherapy (IO) has transformed the treatment paradigm for a wide variety of solid tumours. However, assessment of response can be challenging with conventional radiological imaging (eg, iRECIST), which do...
8.
Cohen S, Kasi A, Hook N, Krainock M, Budde G, Malashevich A, et al.
Case Rep Obstet Gynecol
. 2022 Mar;
2022:9412201.
PMID: 35342654
The number of pregnant women with cancer is on the rise. These patients and their providers encounter complex medical management decisions. Standard-of-care systemic therapy and radiological imaging can impair fetal...
9.
Kasi P, Budde G, Krainock M, Aushev V, Malashevich A, Malhotra M, et al.
J Immunother Cancer
. 2022 Feb;
10(1).
PMID: 35101943
Immune checkpoint inhibitors have shown great promise in treating patients with mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) colorectal cancer (CRC). Although single-agent pembrolizumab has been approved for first-line treatment of...
10.
Schneider C, Krainock M, Malashevich A, Malhotra M, Olshan P, Billings P, et al.
Case Rep Oncol
. 2021 Jul;
14(2):849-853.
PMID: 34248549
Immunotherapy (IO) has increasingly been demonstrated to provide therapeutic benefit to patients with metastatic colorectal cancer (mCRC). However, only a subset of mCRC tumors respond to IO. Monitoring response with...